Award
National Institute of Allergy and Infectious Diseases 1R41AI188733-01A1
A novel Th17-enhancing adjuvant and conserved antigen for protection against viral/bacterial co-infection
Recipient
VISHENARY, LLC
Award Amount
$308,669.00
Ceiling
$308,669.00
Awarded
September 23, 2025
Identifier
1R41AI188733-01A1
Award for developing a vaccine candidate using a novel Th17-enhancing adjuvant and conserved antigen to protect against viral and bacterial co-infection, including preclinical and toxicity studies.
Description
This project involves developing a vaccine candidate with a Th17-inducing NTHi antigen and a novel adjuvant, Romidepsin (RMD). The project includes preclinical studies, toxicity assessments, and aims to establish the optimal vaccine dosage and safety profile for potential clinical trials.